Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Strategic Alliance Partners

Latest from Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Vaccine Protects Most Cancer Patients From COVID-19, But Risk Remains Higher for Patients With Blood Cancers

April 27, 2022

A researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center found the COVID-19 vaccine protected most cancer patients from getting COVID. However, patients with certain types of cancer have a higher and widely varied risk of breakthrough COVID infections after receiving the COVID vaccine.

Fellowship Is a Time for Growth

December 24, 2020

Michael J. Robertson, MD, discusses the value of fellowship, choosing a career path, and the second epiphany that led him to focus on one of the hottest topics in oncology years before it became a viable treatment option.

Dr. O'Neil on Neuroendocrine Tumors

May 22, 2018

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the importance of differentiating between neuroendocrine tumors (NETs).

Dr. Helft Discusses Pancreatic and Carcinoid NETs

April 03, 2018

Paul R. Helft, MD, professor of medicine, Indiana University School of Medicine, Indiana University Health Melvin and Bren Simon Cancer Center, discusses pancreatic and carcinoid neuroendocrine tumors.

Indiana University Researchers Find Precision Medicine Improves Outcomes

October 14, 2016

With the growing body of evidence supporting positive outcomes with the use of precision medicine–based approaches, academic cancer centers are increasingly incorporating genomic technology into standard clinical care.

Summer Research Program Offers First-Hand Experiences

June 14, 2016

The program brings both high-school and undergraduate students from underrepresented populations to the IU School of Medicine's Indianapolis campus. It offers students positive and meaningful firsthand exposure to biomedical and behavioral science careers that might not otherwise present themselves.

Combination Therapies Explored in Pancreatic Cancer Subgroups

March 25, 2016

To address the unmet need for better diagnostic and therapeutic modalities in pancreatic cancer, investigators at the Indiana University School of Medicine have established the Pancreatic Cancer Signature Center at the Indiana University Melvin and Bren Simon Cancer Center.

Olanzapine Shown to Control CINV in Patients With Esophageal, Head and Neck Cancer

June 15, 2015

Olanzapine (Zyprexa) demonstrated an improvement in antinausea effects in patients receiving concurrent highly emetogenic chemotherapy and radiation therapy for advanced stage head and neck and esophageal cancer when compared to fosaprepitant.

The Goodwill of Strangers Helps Build a Unique Resource for Cancer Research

May 24, 2015

Thousands of women have made the selfless choice to literally donate a precious piece of themselves by giving a breast tissue sample to the Susan G. Komen Tissue Bank at the Indiana University Melvin and Bren Simon Cancer Center, a unique resource for researchers worldwide.

IU Simon Cancer Center Teams with OncLive in Strategic Alliance Partnership

March 03, 2015

OncLive and Indiana University Melvin and Bren Simon Cancer Center have joined forces to share news about the center's research and education programs, OncLive announced today. The collaboration is part of OncLive's Strategic Alliance Partnership initiative.

Dr. Einhorn on Improving the Cure Rate and the Burden of Cure in Prostate Cancer

July 01, 2014

Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.